Therapeutic Effect according to Estrogen Dosage on Combined Therapy with Estrogen and Alendronate in Postmenopausal Osteoporosis. |
Kim, Ghi Chan , Jeong, Ho Joong , Ha, Ho Sung , Lee, Sang Jin |
1Department of Physical Medicine & Rehabilitation, Kosin University College of Medicine, Korea. hhs96a@hanmail.net 2Dong-eui Hospital, Korea. |
골다공증에서 알렌드로네이트 투여 시 에스트로젠 용량에 따른 치료 효과 |
김기찬, 정호중, 하호성, 이상진1 |
고신대학교 의과대학 재활의학교실, 1동의병원 재활의학과 |
|
|
|
Abstract |
Objective To compare the difference of bone mineral density (BMD), biochemical markers, and lipid profiles according to dosage of estrogen on combined therapy with estrogen and alendronate in postmenopausal osteoporosis. Method We studied 81 women with postmenopausal osteoporosis (T-score<2.5) from March 2002 to February 2005. Subjects were divided in two groups; Group I (n=36), treated with low dose hormone therapy (HT) (0.3 mg estrogen/1.25 mg MPA (Medroxyprogesterone acetate)) and alendronate, and Group II (n=45), treated with standard dose HT (0.625 mg estrogen/2.5 mg MPA) and alendronate. BMD at the L-spine and femur, osteocalcin, deoxypyridinoline, and lipid profiles were measured at baseline and 1 year after treatment. Results BMD at the L-spine increased significantly in two groups and BMD at the femur increased but showed no statistical differences. Deoxypyridinoline and osteocalcin decreased significantly in two group. Total cholesterol and LDL (low density lipoprotein) cholesterol decreased significantly in two groups, no significant difference was observed between two groups in BMD, osteocalcin, deoxypyridinoline, and lipid profiles. Conclusion We concluded that combined therapy with low dose estrogen and alendronate in postmenopausal osteoporosis showed similar therapeutic effect provied by combined therapy of standard dose estrogen and alendronate. (J Korean Acad Rehab Med 2006; 30: 247-253) |
Key Words:
Postmenopausal osteoporosis, Alendronate, Low dose estrogen, Bone mineral density, Lipid profile |
|